Cellectar Biosciences Investor Relations Material
Latest events
Q4 2023
Cellectar Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Cellectar Biosciences Inc
Access all reports
Cellectar Biosciences Inc (CLRB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. Leveraging its proprietary phospholipid drug conjugate (PDC) delivery platform, Cellectar aims to develop targeted therapies designed to enhance treatment outcomes by selectively delivering cancer-killing agents to tumor cells, minimizing the impact on normal tissues. The company is headquartered in Florham Park, New Jersey, and its shares are listed on the Nasdaq.
Latest articles
From Timber to Luxury: The Story of François-Henri Pinault and Kering
Dive into the story of François-Henri Pinault, from his rise in the family timber business to leading Kering into a global luxury powerhouse.
7 May 2024
Companies That Had Their IPO in 1994: A Cautious Market
An overview of the year 1994 in the stock and IPO market, as the interest rates soared and the bond market collapsed.
6 May 2024
The World of Luxury: Creating and Selling Desirability
Dive into the enchanting world of high-end allure, where the art of exclusivity shapes desire, turning luxury into an emblem of unique prestige.
6 May 2024
Ticker symbol
Country
🇺🇸 United States